151 related articles for article (PubMed ID: 22038593)
1. Hypomethylation of the thymosin β(10) gene is not associated with its overexpression in non-small cell lung cancer.
Lee SM; Na YK; Hong HS; Jang EJ; Yoon GS; Park JY; Kim DS
Mol Cells; 2011 Oct; 32(4):343-8. PubMed ID: 22038593
[TBL] [Abstract][Full Text] [Related]
2. Thymosin β10 promotes tumor-associated macrophages M2 conversion and proliferation via the PI3K/Akt pathway in lung adenocarcinoma.
Zeng J; Yang X; Yang L; Li W; Zheng Y
Respir Res; 2020 Dec; 21(1):328. PubMed ID: 33349268
[TBL] [Abstract][Full Text] [Related]
3. TMSB10 acts as a biomarker and promotes progression of clear cell renal cell carcinoma.
Pan Q; Cheng G; Liu Y; Xu T; Zhang H; Li B
Int J Oncol; 2020 May; 56(5):1101-1114. PubMed ID: 32319572
[TBL] [Abstract][Full Text] [Related]
4. Thymosin beta 10 is a key regulator of tumorigenesis and metastasis and a novel serum marker in breast cancer.
Zhang X; Ren D; Guo L; Wang L; Wu S; Lin C; Ye L; Zhu J; Li J; Song L; Lin H; He Z
Breast Cancer Res; 2017 Feb; 19(1):15. PubMed ID: 28179017
[TBL] [Abstract][Full Text] [Related]
5. PTEN/AKT upregulation of TMSB10 contributes to lung cancer cell growth and predicts poor survival of the patients.
Li J; Zhou S; Li H; Xu Y; Zhou N; Liu R
Biosci Biotechnol Biochem; 2021 Mar; 85(4):805-813. PubMed ID: 33686397
[TBL] [Abstract][Full Text] [Related]
6. Epigenetic inactivation of Homeobox A5 gene in nonsmall cell lung cancer and its relationship with clinicopathological features.
Kim DS; Kim MJ; Lee JY; Lee SM; Choi JY; Yoon GS; Na YK; Hong HS; Kim SG; Choi JE; Lee SY; Park JY
Mol Carcinog; 2009 Dec; 48(12):1109-15. PubMed ID: 19554572
[TBL] [Abstract][Full Text] [Related]
7. Epigenetic inactivation of checkpoint kinase 2 gene in non-small cell lung cancer and its relationship with clinicopathological features.
Kim DS; Kim MJ; Lee JY; Lee SM; Choi JE; Lee SY; Park JY
Lung Cancer; 2009 Aug; 65(2):247-50. PubMed ID: 19362748
[TBL] [Abstract][Full Text] [Related]
8. DNMT1 maintains the methylation of miR-152-3p to regulate TMSB10 expression, thereby affecting the biological characteristics of colorectal cancer cells.
Wang C; Ma X; Zhang J; Jia X; Huang M
IUBMB Life; 2020 Nov; 72(11):2432-2443. PubMed ID: 32918845
[TBL] [Abstract][Full Text] [Related]
9. TMSB10 Promotes Progression of Clear Cell Renal Cell Carcinoma via JUN Transcription Regulation.
Wang C; He Y; You Z; Chen X
Ann Clin Lab Sci; 2022 Mar; 52(2):230-239. PubMed ID: 35414502
[TBL] [Abstract][Full Text] [Related]
10. LINE-1 hypomethylation is associated to specific clinico-pathological features in Stage I non-small cell lung cancer.
Imperatori A; Sahnane N; Rotolo N; Franzi F; Nardecchia E; Libera L; Romualdi C; Cattoni M; Sessa F; Dominioni L; Furlan D
Lung Cancer; 2017 Jun; 108():83-89. PubMed ID: 28625654
[TBL] [Abstract][Full Text] [Related]
11. Aberrant promoter methylation in Chinese patients with non-small cell lung cancer: patterns in primary tumors and potential diagnostic application in bronchoalevolar lavage.
Chan EC; Lam SY; Tsang KW; Lam B; Ho JC; Fu KH; Lam WK; Kwong YL
Clin Cancer Res; 2002 Dec; 8(12):3741-6. PubMed ID: 12473584
[TBL] [Abstract][Full Text] [Related]
12. Increased expression of 17-beta-hydroxysteroid dehydrogenase type 1 in non-small cell lung cancer.
Drzewiecka H; Gałęcki B; Jarmołowska-Jurczyszyn D; Kluk A; Dyszkiewicz W; Jagodziński PP
Lung Cancer; 2015 Feb; 87(2):107-16. PubMed ID: 25564397
[TBL] [Abstract][Full Text] [Related]
13. Aberrant promoter methylation of multiple genes in non-small cell lung cancers.
Zöchbauer-Müller S; Fong KM; Virmani AK; Geradts J; Gazdar AF; Minna JD
Cancer Res; 2001 Jan; 61(1):249-55. PubMed ID: 11196170
[TBL] [Abstract][Full Text] [Related]
14. Thymosin β 10 is overexpressed and associated with unfavorable prognosis in hepatocellular carcinoma.
Song C; Su Z; Guo J
Biosci Rep; 2019 Mar; 39(3):. PubMed ID: 30787051
[TBL] [Abstract][Full Text] [Related]
15. RhoB is frequently downregulated in non-small-cell lung cancer and resides in the 2p24 homozygous deletion region of a lung cancer cell line.
Sato N; Fukui T; Taniguchi T; Yokoyama T; Kondo M; Nagasaka T; Goto Y; Gao W; Ueda Y; Yokoi K; Minna JD; Osada H; Kondo Y; Sekido Y
Int J Cancer; 2007 Feb; 120(3):543-51. PubMed ID: 17096327
[TBL] [Abstract][Full Text] [Related]
16. Association of FOSB exon 4 unmethylation with poor prognosis in patients with late‑stage non‑small cell lung cancer.
Kim DS; Lee WK; Park JY
Oncol Rep; 2020 Feb; 43(2):655-661. PubMed ID: 31894310
[TBL] [Abstract][Full Text] [Related]
17. [Up-regulation of DLK1 in non-small cell lung cancer and the relevant molecular mechanism].
Zhang SS; Tan JJ; Li L; Chen WT; Han NJ; Guo SP; Zheng S; Liu Y; Gao YN
Zhonghua Zhong Liu Za Zhi; 2016 Jul; 38(7):510-4. PubMed ID: 27531264
[TBL] [Abstract][Full Text] [Related]
18. Promoter methylation of the RGC32 gene in nonsmall cell lung cancer.
Kim DS; Lee JY; Lee SM; Choi JE; Cho S; Park JY
Cancer; 2011 Feb; 117(3):590-6. PubMed ID: 20862745
[TBL] [Abstract][Full Text] [Related]
19. Death-associated protein kinase promoter methylation correlates with clinicopathological and prognostic features in nonsmall cell lung cancer patients: A cohort study.
Yang XY; Zhang J; Yu XL; Zheng GF; Zhao F; Jia XJ
J Cancer Res Ther; 2018; 14(Supplement):S65-S71. PubMed ID: 29578152
[TBL] [Abstract][Full Text] [Related]
20. The methylation status and protein expression of CDH1, p16(INK4A), and fragile histidine triad in nonsmall cell lung carcinoma: epigenetic silencing, clinical features, and prognostic significance.
Nakata S; Sugio K; Uramoto H; Oyama T; Hanagiri T; Morita M; Yasumoto K
Cancer; 2006 May; 106(10):2190-9. PubMed ID: 16598757
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
